Remove 2020 Remove Documentation Remove Hospitals
article thumbnail

Vertical pharma: How sector convergence can erase digital health siloes

pharmaphorum

Closer collaboration with universities and academia is another trend, says Ekdahl, adding that the University of Gothenburg, as an example, is currently working with the university hospital and a technical college to provide doctors with a specialised digitalisation training programme. Innovation versus regulation.

article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

Interestingly, the 340B law was actually included in a veterans healthcare bill (the Veterans Health Care Act) that also established a separate drug pricing program for veterans hospitals. It also raised the DSH payment cap for some rural and small urban hospitals to 12%. 340B providers expressed significant concern.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vision for consultant pharmacists by 2030 unveiled by RPS

Hospital Pharmacy Europe

Professor Nicola Stoner, chair of the RPS Consultant Pharmacist Group, said: ‘This document sets out an ambitious and exciting vision for the role of the consultant pharmacist following our very successful consultant pharmacist summit last year.

article thumbnail

EU-funded project encourages use of simulation in drug development

pharmaphorum

The project is coordinated by the University of Bologna and funded by the European Union’s Horizon 2020 research and innovation programme that involves more than a dozen partner institutions, including Italian startup InSilicoTrials. Deutsches Institut fu?r r Normung (DIN) will act as a standardisation body.

article thumbnail

Rare diseases have tenfold higher impact on healthcare costs; study

pharmaphorum

The burden was chiefly driven by direct costs like medicinal products, inpatient and outpatient hospital visits and home healthcare, as well as mortality costs, calculated at $130,000 per year lost. The highest burden was posed by metabolic diseases and neurological disorders, which were both upwards of $300,000 PPPY.

article thumbnail

Hidden compliance risks for life sciences companies

pharmaphorum

The industry’s multi-level relationships with government-linked customers, such as hospitals and doctors, puts them squarely in the sights of enforcement agencies like the Department of Justice (DOJ) and Securities and Exchange Commission (SEC). In 2020, life science firms accounted for a third of the SEC’s enforcement actions.

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Gilenya is an oral medication for multiple sclerosis.